Elicio Therapeutics, Inc. (ELTX)
ELTX moved a median of 0.00% 30 minutes after news, and -1.83% by the close. How ELTX actually reacts to news — the realized, point-in-time move the market made, measured across 237 labeled events over the last three years with zero look-ahead.
ELTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 218 |
| 30-min | 0.00% | 43% | 228 |
| 60-min | 0.00% | 47% | 228 |
| to close | -1.83% | 37% | 234 |
| Middle 50% of ELTX reactions | -1.23% to +1.60% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 237 |
Half of all Elicio Therapeutics, Inc. news events land between -1.23% and +1.60% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ELTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 12 | +1.56% | 67% | -0.14% |
| Rating reiterations | 17 | -0.71% | 41% | +0.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ELTX ranks against every other measured name →
That’s how ELTX usually reacts — get an email when it moves on news →Email me when ELTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ELTX's baseline. Nothing else.
Recent ELTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A Elicio Therapeutics, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -0.84% | -1.05% | |
| Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 | Press release | GlobeNewswire | +1.86% | +0.00% | |
| Form 8-K Elicio Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -3.98% | -0.99% | |
| Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -0.18% | -4.93% | |
| Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | -1.63% | -2.61% | |
| Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -0.73% | -2.21% | |
| Form 10-Q Elicio Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.73% | -2.21% | |
| Form 8-K Elicio Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -2.21% | |
| Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma | Press release | GlobeNewswire | +1.88% | — | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -1.33% | +3.26% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.29% | +2.35% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +3.08% | +6.75% | |
| Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering | Press release | GlobeNewswire | -2.73% | -15.15% | |
| Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +4.13% | -2.80% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, Inc. (ELTX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.06% | -5.43% | |
| Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | Press release | GlobeNewswire | +0.83% | -11.05% | |
| Form 8-K Elicio Therapeutics, For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | -11.05% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.38% | -2.37% | |
| Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes | Press release | GlobeNewswire | -2.00% | +0.00% | |
| Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.94% | -3.03% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -2.00% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, Inc. (ELTX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | +4.97% | |
| Form 8-K Elicio Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -0.77% | -3.35% | |
| Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer | Press release | GlobeNewswire | -3.01% | +49.29% | |
| Form 8-K Elicio Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -3.01% | +49.29% | |
| Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) | Press release | PR Newswire | -3.01% | +49.29% | |
| Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer | Press release | GlobeNewswire | -6.07% | -12.26% | |
| Form 8-K Elicio Therapeutics, For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -6.07% | -12.26% | |
| Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology | Press release | GlobeNewswire | +2.78% | +6.88% | |
| Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -2.37% | -12.16% | |
| Form 10-Q Elicio Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.37% | -12.16% | |
| Form 8-K Elicio Therapeutics, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -2.37% | -12.16% | |
| Elicio Therapeutics to Present at the Bank of America Healthcare Conference | Press release | GlobeNewswire | -0.87% | +2.21% | |
| Form 10-K/A Elicio Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.87% | +2.21% | |
| Elicio Therapeutics Reports Inducement Grants | Press release | GlobeNewswire | +0.00% | +2.02% | |
| Elicio Therapeutics Reports Inducement Grants | Press release | GlobeNewswire | -0.33% | +0.33% | |
| Form EFFECT Elicio Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.33% | +0.33% | |
| Form 8-K Elicio Therapeutics, For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | -1.22% | |
| Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +0.22% | +7.96% | |
| Form 10-K Elicio Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.22% | +7.96% | |
| Form 8-K Elicio Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +7.96% | |
| Form S-3/A Elicio Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.22% | +7.96% | |
| Form S-8 Elicio Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.22% | +7.96% | |
| Form S-3/A Elicio Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +3.28% | -6.72% | |
| Form S-3 Elicio Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +6.33% | +6.79% | |
| Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +2.30% | +9.91% | |
| Elicio Therapeutics Reports Inducement Grants | Press release | GlobeNewswire | +6.51% | +4.22% | |
| Elicio Therapeutics Reports Inducement Grants | Press release | GlobeNewswire | +12.53% | +5.50% | |
| Elicio Therapeutics Reports Inducement Grants | Press release | GlobeNewswire | +0.12% | -4.23% | |
| Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial | Press release | GlobeNewswire | +0.00% | +3.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ELTX section they belong to.
Where else ELTX is measured.
ELTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Elicio Therapeutics, Inc.'s median reaction calculated?
Every labeled ELTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 237 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ELTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ELTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.